SRA International (SRX) Awarded $24.9 Million Contract From CDC
More News related to SRX
- David H. Langstaff, Government Services Veteran, Named Special Advisor to General Atlantic
- SRA Schedules Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
- Matrex Exhibits Wins Best Overall Web Design in 7th Annual American Business Awards(SM)
- SRA Announces First Partner for FAA National Airspace System Integration Support Contract (NISC III)
- SRA International (SRX) Receives $63 Million Contract
SRA International, Inc. (NYSE: SRX) has won a contract with the Centers for Disease Control and Prevention (CDC) Division of Select Agents and Toxins to provide laboratory support services to the Select Agent Program. Awarded in September, the contract is a re-compete of work the company has supported since 2002 through the acquisition of Constella Group. It has an estimated value of $24.9 million over five years, if all options are exercised.
Under the contract, SRA will continue to help CDC track the possession, use and transfer of select agents in the U.S. (Select agents are biological agents and toxins that have the potential to pose a threat to public health and safety if released into the environment.)
SRA International, Inc. (SRA) is a provider of technology and consulting services and solutions to clients in national security, civil government, and global health.[SM]
Related Categories
Corporate NewsStocks Mentioned
+8.39Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
